Related Experiment Video
Updated: Aug 2, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study
J F Money-Kyrle1, F Bates, J Ready
1Kobler Centre, St Stephen's Clinic, London, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 1, 1993
Summary
Liposomal daunorubicin (DaunoXome) showed effectiveness in treating advanced AIDS-related Kaposi's sarcoma. While generally well-tolerated, the treatment caused significant neutropenia in some patients.
Area of Science:
- Oncology
- Hematology
- Infectious Diseases
Background:
- AIDS-related Kaposi's sarcoma (KS) is an opportunistic malignancy.
- Effective and safe treatment options for advanced KS are crucial.
- Liposomal daunorubicin (DaunoXome) is an investigational agent for KS.
Purpose of the Study:
- To evaluate the efficacy and safety of liposomal daunorubicin in patients with advanced AIDS-related Kaposi's sarcoma.
- To assess treatment response, including lesion changes and overall survival.
- To monitor clinical, biochemical, and hematological toxicities.
Main Methods:
- A non-randomized Phase II clinical trial was conducted.
- Eleven homosexual men with advanced KS were enrolled.
- Target lesions were measured; clinical and laboratory toxicities were assessed.
Main Results:
- Ten subjects were evaluated, with partial response in four (two relapsed).
- Six subjects showed stabilization of KS, with four maintained until trial end.
- The drug was generally well-tolerated, but severe neutropenia occurred in three subjects.
Conclusions:
- Liposomal daunorubicin demonstrated efficacy in treating advanced AIDS-related Kaposi's sarcoma.
- The agent was generally well-tolerated, with manageable side effects.
- Hematological toxicity, specifically neutropenia, was the primary concern.
